After greater than 30 years since she was first identified with a myeloproliferative neoplasm (MPN), a sort of blood most cancers,
Baker, who is predicated in the UK, lately sat down for an interview with CURE alongside Dr. Marina Kremyanskaya, the lead investigator of
Baker had acquired a analysis of important thrombocythemia (ET) in 1991, adopted by polycythemia vera (PV) in 2004.
“From the science neighborhood and great docs like Marina, to simply hear that there are research like this, I promise you, is music to my ears,” Baker advised CURE.
Transcript
What are your ideas on the SANRECO trial?
There will not be plenty of choices for sufferers with PV, and so it’s so thrilling to listen to of one thing new. You recognize, not all of us can tolerate a few of the present medication, and I actually have had different unwanted side effects from different medication I’ve tried. So I feel, from the science neighborhood and great docs like Marina, to simply hear that there are research like this, I promise you, is music to my ears. You recognize, I hear from so many, as a result of I am a part of this charity known as MPN Voice and I meet with plenty of sufferers with PV, and I hear the identical factor, the identical form of unwanted side effects. And thanks for Marina for highlighting itch, which is one other huge facet impact for lots of people. And , it will likely be great. It is going to be completely great to have one thing like this come to fruition for all of us sufferers.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling,
